



Grant of Stock Options and Award of Restricted Stock Units

San Diego, California and Sydney, Australia (Wednesday, 27 July 2016 AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) announces that on 22 July 2016, a total of 23,600 options to purchase common stock (equivalent to 236,000 CDIs) were granted and 12,600 restricted stock units (equivalent to 126,000 CDIs) were awarded to two directors of the Company under the Company’s Amended and Restated 2010 Equity Incentive Plan. These grants and awards were approved by the Company’s stockholders at its Annual General Meeting held 26 May 2016. Details of the stock option grants and restricted stock unit awards are provided in the attached Appendix 3B.

Following these grants and awards, there are outstanding options to purchase a total of 6,469,025 shares of common stock (equivalent to 64,690,250 CDIs) and 872,000 restricted stock units subject to vesting under the Company’s equity incentive plans.

About REVA

REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable scaffolds, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s *Fantom*[®] scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require regulatory approval before it can commercialize *Fantom* or any other product.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on March 10, 2016, and as may be updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**United States
Investor & Media Enquiries:**
REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

**Australia
Investor Enquiries:**
Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

**Australia
Media Enquiries:**
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O'Connell Street, Sydney NSW 2000 • +61 2 9237 2800

ARBN 146 505 777 • REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

REVA Medical, Inc.

ARBN

146 505 777

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|--|
| 1 | +Class of +securities issued or to be issued | 1) Options to purchase shares of common stock ("Options") (unquoted).
2) Restricted stock units ("RSUs") (unquoted). |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 1) 23,600 Options (equivalent to 236,000 CDIs).
2) 12,600 RSUs (equivalent to 126,000 CDIs). |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | 1) 23,600 Options approved by stockholders. Each Option is issued for no monetary consideration and, upon vesting, entitles the holder to purchase one share of common stock for a price of US\$8.90. Each Option has a 10-year term, is exercisable upon vesting, and is issued in accordance with the Company's Amended and Restated 2010 Equity Incentive Plan. Options vest in equal quarterly instalments over a one-year period; initial vesting date is 26 August 2016. Vesting is conditioned upon the holder's remaining in service to the Company at the vesting date.
2) 12,600 RSUs approved by stockholders. Each RSU is issued for no monetary consideration and is issued in accordance with the Company's Amended and Restated 2010 Equity Incentive Plan. Each RSU entitles the holder to one share of common stock upon vesting. The RSUs vest upon the earlier of one year from the date of award or the day prior to the Company's 2017 Annual Meeting. Vesting is conditioned upon the holder's remaining in service to the Company at the vesting date. |

+ See chapter 19 for defined terms.

For personal use only

<p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>1) The holders of Options are not entitled to any rights of stockholders. Upon the exercise of the Options for shares of common stock, the shares of common stock (which can be converted to CDIs) will rank equally in all respects with the existing class of quoted securities.</p> <p>2) The holders of RSUs are not entitled to any rights of stockholders. Upon the vesting of the RSUs, the holder will receive shares of common stock (which can be converted to CDIs), which will rank equally in all respects with the existing class of quoted securities.</p>
<p>5 Issue price or consideration</p>	<p>1) No monetary consideration is payable for the issuance of the Options.</p> <p>2) No monetary consideration is payable for the issuance of the RSUs.</p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>1) Options were granted as incentive and inducement for two existing directors.</p> <p>2) RSUs were awarded for incentive and inducement for two existing directors.</p>
<p>6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h for securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>Yes.</p>
<p>6b The date the security holder resolution under rule 7.1A was passed</p>	<p>26 May 2016.</p>
<p>6c Number of +securities issued without security holder approval under rule 7.1</p>	<p>Not applicable.</p>
<p>6d Number of +securities issued with security holder approval under rule 7.1A</p>	<p>Not applicable.</p>
<p>6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)</p>	<p>Not applicable.</p>
<p>6f Number of +securities issued under an exception in rule 7.2</p>	<p>1) 23,600 Options (Listing Rule 7.2, exception 9).</p> <p>2) 12,600 RSUs (Listing Rule 7.2, exception 9).</p>

+ See chapter 19 for defined terms.

6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

Not applicable.

6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

Not applicable.

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Remaining capacity under Listing Rule 7.1: 6,405,673 shares of common stock (equivalent to 64,056,729 CDIs).

Remaining capacity under Listing Rule 7.1A: 4,270,449 shares of common stock (equivalent to 42,704,486 CDIs).

Please see Annexure 1 for further details.

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.

1) Options were granted on 22 July 2016.
2) RSUs were awarded on 22 July 2016.

Number	+Class
427,044,860 CDIs are quoted, assuming all shares of common stock are held as CDIs (a total of 42,704,486 common shares are issued and outstanding).	CDIs

Number	+Class
472,925 options (over 472,925 shares of common stock or 4,729,250 CDIs).	Options issued under the 2001 Stock Option/Stock Issuance Plan.
5,996,100 options (over 5,996,100 shares of common stock or 59,961,000 CDIs).	Options issued under the Amended and Restated 2010 Equity Incentive Plan.
872,000 RSUs (over 872,000 shares of common stock or 8,720,000 CDIs).	RSUs issued under the Amended and Restated 2010 Equity Incentive Plan.
250 convertible notes.	Convertible notes issued under Convertible Note Deed dated 25 September 2014.

+ See chapter 19 for defined terms.

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable.

Part 2 - Pro rata issue

11 Is security holder approval required?

Not applicable.

12 Is the issue renounceable or non-renounceable?

Not applicable.

13 Ratio in which the +securities will be offered

Not applicable.

14 +Class of +securities to which the offer relates

Not applicable.

15 +Record date to determine entitlements

Not applicable.

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

Not applicable.

17 Policy for deciding entitlements in relation to fractions

Not applicable.

18 Names of countries in which the entity has security holders who will not be sent new offer documents

Not applicable.

Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

19 Closing date for receipt of acceptances or renunciations

Not applicable.

20 Names of any underwriters

Not applicable.

21 Amount of any underwriting fee or commission

Not applicable.

22 Names of any brokers to the issue

Not applicable.

23 Fee or commission payable to the broker to the issue

Not applicable.

24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders

Not applicable.

25 If the issue is contingent on security holders' approval, the date of the meeting

Not applicable.

26 Date entitlement and acceptance form and offer documents will be sent to persons entitled

Not applicable.

27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

Not applicable.

28 Date rights trading will begin (if applicable)

Not applicable.

+ See chapter 19 for defined terms.

- 29 Date rights trading will end (if applicable) Not applicable.
- 30 How do security holders sell their entitlements *in full* through a broker? Not applicable.
- 31 How do security holders sell *part* of their entitlements through a broker and accept for the balance? Not applicable.
- 32 How do security holders dispose of their entitlements (except by sale through a broker)? Not applicable.
- 33 ⁺Issue date Not applicable.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of ⁺securities (tick one)
 - (a) ⁺Securities described in Part 1
 - (b) All other ⁺securities
 Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders
- 36 If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories
 - 1 - 1,000
 - 1,001 - 5,000
 - 5,001 - 10,000
 - 10,001 - 100,000
 - 100,001 and over
- 37 A copy of any trust deed for the additional ⁺securities

Entities that have ticked box 34(b)

- 38 Number of ⁺securities for which ⁺quotation is sought Not applicable.
- 39 ⁺Class of ⁺securities for which quotation is sought Not applicable.

⁺ See chapter 19 for defined terms.

40	<p>Do the ⁺securities rank equally in all respects from the ⁺issue date with an existing ⁺class of quoted ⁺securities?</p> <p>If the additional ⁺securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	Not applicable.	
41	<p>Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another ⁺security, clearly identify that other ⁺security)</p>	Not applicable.	
42	<p>Number and ⁺class of all ⁺securities quoted on ASX (including the ⁺securities in clause 38)</p>	Number	⁺ Class
		Not applicable.	Not applicable.

⁺ See chapter 19 for defined terms.

Quotation agreement

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:
(Company Secretary)

Date: 27 July 2016

Print name: Katrina L. Thompson

== == == == ==

+ See chapter 19 for defined terms.

For personal use only

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	337,077,780 CDIs (assuming all shares of common stock were held as CDIs).
Add the following: <ul style="list-style-type: none"> • Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: <ul style="list-style-type: none"> • <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	8,996,708 shares of common stock (equivalent to 89,967,080 CDIs).
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil
“A”	427,044,860 CDIs (assuming all shares of common stock were held as CDIs).

+ See chapter 19 for defined terms.

For personal use only

Step 2: Calculate 15% of “A”	
“B”	0.15
Multiply “A” by 0.15	64,056,729 CDIs (assuming all shares of common stock were held as CDIs).
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p>Note:</p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	Nil
“C”	Nil
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	64,056,729 CDIs (assuming all shares of common stock were held as CDIs).
<p>Subtract “C”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	Nil
Total [“A” x 0.15] – “C”	<p>64,056,729 CDIs (assuming all shares of common stock were held as CDIs).</p> <p><i>Note: this is the remaining placement capacity under rule 7.1</i></p>

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	427,044,860 CDIs (assuming all shares of common stock were held as CDIs).
Step 2: Calculate 10% of “A”	
“D”	0.10
Multiply “A” by 0.10	42,704,486 CDIs (assuming all shares of common stock were held as CDIs).
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A <i>Notes:</i> <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	Nil
“E”	Nil
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
“A” x 0.10 <i>Note: number must be same as shown in Step 2</i>	42,704,486 CDIs (assuming all shares of common stock were held as CDIs).
Subtract “E” <i>Note: number must be same as shown in Step 3</i>	Nil
Total [“A” x 0.10] – “E”	42,704,486 CDIs (assuming all shares of common stock were held as CDIs). <i>Note: this is the remaining placement capacity under rule 7.1A</i>

+ See chapter 19 for defined terms.